GIANNECCHINI, SIMONE
 Distribuzione geografica
Continente #
NA - Nord America 3.233
EU - Europa 1.856
AS - Asia 431
AF - Africa 16
OC - Oceania 5
SA - Sud America 1
Totale 5.542
Nazione #
US - Stati Uniti d'America 3.209
IT - Italia 443
PL - Polonia 338
IE - Irlanda 330
SE - Svezia 225
UA - Ucraina 183
HK - Hong Kong 158
JO - Giordania 125
DE - Germania 105
CN - Cina 85
FI - Finlandia 71
GB - Regno Unito 70
RU - Federazione Russa 49
CA - Canada 24
SG - Singapore 17
TR - Turchia 15
SC - Seychelles 14
FR - Francia 12
BE - Belgio 8
CH - Svizzera 8
IN - India 8
VN - Vietnam 8
ES - Italia 7
JP - Giappone 6
AT - Austria 4
AU - Australia 3
IR - Iran 3
KZ - Kazakistan 3
NL - Olanda 3
NZ - Nuova Zelanda 2
CL - Cile 1
EG - Egitto 1
KR - Corea 1
MM - Myanmar 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 5.542
Città #
Fairfield 479
Warsaw 338
Dublin 330
Chandler 311
Jacksonville 247
Ashburn 228
Woodbridge 209
Seattle 184
Houston 179
Cambridge 170
Wilmington 153
Lawrence 128
Altamura 127
Florence 111
Princeton 100
Ann Arbor 91
Hong Kong 79
Medford 61
Beijing 55
Buffalo 49
Boston 44
Boardman 43
San Diego 40
Milan 32
Moscow 27
Los Angeles 19
Norwalk 17
Shanghai 16
Singapore 16
Toronto 14
Frankfurt Am Main 12
Hillsboro 12
West Jordan 12
London 11
Andover 9
Bern 8
Brussels 8
Dong Ket 8
Rome 8
Saint Petersburg 8
Auburn Hills 7
Falls Church 7
Izmir 7
Barcelona 6
New York 6
Chiswick 5
Lucca 5
Montottone 5
Verona 5
Chicago 4
Guangzhou 4
Kilburn 4
Menlo Park 4
Naples 4
Ottawa 4
San Giovanni Valdarno 4
Siena 4
Thiene 4
Vienna 4
Alvignano 3
Cerro Maggiore 3
Piacenza 3
Redmond 3
Sesto Fiorentino 3
Trumbull 3
Almaty 2
Castelliri 2
Cattolica 2
Central 2
Cheltenham 2
Coimbatore 2
Corzano 2
Groningen 2
Hakusan 2
Hounslow 2
Istanbul 2
Kiel 2
Laurel 2
Misano Adriatico 2
Montréal 2
Munich 2
Pisa 2
Pontassieve 2
Prato 2
Pune 2
Québec 2
Redwood City 2
San Piero A Sieve 2
Shenzhen 2
Tiruchi 2
Washington 2
Wuxi 2
Astana 1
Auckland 1
Barrie 1
Birmingham 1
Bitritto 1
Bologna 1
Bremen 1
Böblingen 1
Totale 4.166
Nome #
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 215
Investigation of in vitro replication features of wild ducks and turkey H7N3 influenza viruses: possibile role in interspecies transmission. 180
COVID-19 Salivary Signature: Diagnostic and Research Opportunities 108
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 100
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. 100
Blood levels of TT virus following immune stimulation with influenza or hepatitis B vaccine. 96
Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. 96
Comparison of in vitro replication features of H7N3 influenza viruses from wild ducks and turkeys: potential implications for interspecies transmission. 95
Characterization of human H1N1 influenza virus variants selected In vitro with zanamivir in the presence of sialic acid-containing molecules 93
Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017 93
Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env 91
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. 90
During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. 86
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. 84
BK polyomavirus microRNA levels in exosomes are modulated by non-coding control region activity, and down-regulate viral replication when delivered to non-infected cells prior to infection. 83
Utility of droplet digital PCR for the quantitative detection of polyomavirus JC in clinical samples 83
Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. 82
Polyomavirus microRNAs circulating in biological fluids during viral persistence 82
The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML 81
Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro. 80
Investigation on torquetenovirus (TTV) microRNA transcriptome in vivo 80
Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. 79
A retro-inverso analogue of the antiviral octapeptide C8 inhibits feline immunodeficiency virus in serum. 79
The inhibition of a plant proteinase by lysine copolymers is modulated by the hydrophobicity of interposed amino acid side chains. 77
Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates. 77
AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. 77
Dissection of seroreactivity against the tryptophan-rich motif of feline immunodeficiency virus transmembrane glycoprotein. 77
Reassortment ability of the 2009 pandemic H1N1 influenza virus with circulating human and avian influenza viruses: Public health risk implications 77
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy 76
Polyomavirus microRNA in saliva reveals persistent infectious status in the oral cavity 71
Development of antiviral fusion inhibitors: short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus 71
Oligonucleotides derived from the packaging signal at the 5’ end of the viral PB2 segment specifically inhibit influenza virus in vitro 71
DDX3X helicase inhibitors as new strategy to fight West Nile Virus infection. 71
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. 70
The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. 69
Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. 66
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. 66
INCUBATION TIME FOR FELINE IMMUNODEFICIENCY VIRUS CULTURES. 64
Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects 64
Multiple signatures of the JC polyomavirus in paired normal and altered colorectal mucosa indicate a link with human colorectal cancer, but not with cancer progression. 64
Antiviral activity against SARS-CoV-2 of conformationally constrained helical peptides derived from angiotensin-converting enzyme-2. 63
Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein 62
Torquetenovirus detection in exosomes enriched vesicles circulating in human plasma samples. 62
Molecular adaptation of an H7N3 wild duck influenza virus following experimental multiple passages in quail and turkey. 61
Evolution of two amino acid positions governing broad neutralization resistence in a strain of feline immunodeficiency virus over 7 years of persistence in cats. 60
Small RNAs targeting the 5' end of the viral polymerase gene segments specifically interfere with influenza type A virus replication 60
Detection of polyomavirus JC DNA and anti-JCV antibody in MS patients under natalizumab therapy. 59
Pancreas rejection after pandemic influenzavirus A(H1N1)vaccination or infection: a report of two cases 58
Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the Feline Immunodeficiency Virus and its lipoylated analogue in micellar systems. 57
Increased pathogenicity and shedding in chickens of a wild bird origin LPAI virus of the H7N3 subtype following multiple in vivo passages in quail and turkey. 54
Sudies on AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. 52
Are there lessons that can be learned from the FIV model ? 51
Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy 51
Role of Env in the resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV, as determined using a chimeric virus 50
Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19 50
Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in V4 region of the surface glycoprotein. 48
Effect of enzymatic deglycosylation on feline immunodeficiency virus sensitivity to antibody-mediated neutralization. 48
Changes in the SU can modulate the susceptibility of feline immunodeficiency virus to TM-derived entry inhibitors. 47
Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples. 46
I segnali di packaging alle estremità 5’ della regione codificante dei geni PA, PB1, E PB2 del virus dell’influenza come potenziali bersagli per lo sviluppo di antivirali. 44
A unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 43
Volatiles and Antifungal-Antibacterial-Antiviral Activity of South African Salvia spp. Essential Oils Cultivated in Uniform Conditions 42
In vitro selection of a human H1N1 influenza virus with zanamivir in presence of sialic acid-containing molecules changes its susceptibility to this inhibitor through substitutions in the neuraminidase and hemagglutinin. 41
Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizating antibodies. 41
Single-round virus replication assay for assisting the design of small molecules inhibiting HIV entry in host cells. 40
Analisi dell’espressione di microRNA prodotti dal Polyomavirus JC. 40
Polyomavirus JC microRNAs expression after infection in vitro. 39
SARS-CoV-2: What Can Saliva Tell Us? 37
Selezione in vitro di varianti virali di virus dell’ influenza aviaria H7N3 dell’anatra in presenza di sialogangliosidi. 36
Antibodies generated in cats by a lipopeptide reproducing the MPER of the feline immunodeficiency virus TM enhance virus infectivity 36
Foamy virus derived vector as a tool to vaccinate against feline immunodeficiency virus. 36
Detection of polyomavirus JC DNA and anti-JCV antibody in MS patients under natalizumab therapy. 34
Erratum: Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: A report of two cases (Transplant International (2011) 24 (e28)) 34
Detection of Polyomavirus microRNA-5p Expression in Saliva Short-Term after Kidney Transplantation 33
Screening of the essential oil effects on human H1N1 influenza virus infection: an in vitro study in MDCK cells 32
null 30
Evidence of the mechanism by which polyomaviruses exploit the extracellular vesicle delivery system during infection 30
Ricerca del Poliomavirus JC in pazienti con malattie reumatiche sottoposti ad un trattamento a lungo termine con infliximab. 29
West Nile virus seroprevalence in the Italian Tuscany region from 2016 to 2019 28
Extracellular vesicles engagement during respiratory viruses infection 27
Development of multiplex RT-PCR specific for the eight genomic segments of avian influenza A H7N3 viruses. 26
New influenza virus type A (H1N1), isolated in Florence. 26
Development and in vitro characterization of short modified peptide inhibitors derived from TM gp of FIV for in vivo testing. 26
Quantification of torque teno virus (TTV) DNA in saliva and plasma samples in patients at short time before and after kidney transplantation 26
Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19 26
Development of new antivirals against the influenza type A viruses based on small RNAs targeting the packaging signal of the polymarases gene coding region. 25
Antiviral activity of oligonucleotides targeting the SARS-CoV-2 genomic RNA stem-loop sequences within the 3’-end of the ORF1b. 25
A retroinverso peptide reproducing the Trp-rich motif of the FIV TM has favorable pharmacological traits and markedly reduces viral loads in a short-monotherapy experiment. 24
Packaging signals in the 5' coding region of influenza virus PA, PB1, and PB2 genes as potential target to develop oligonucleotide based antiviral molecole. 24
Polyomavirus JC detection in patients with rheumatic disease after a long-term treatment with infliximab. 21
Investigation of reassortment ability of pandemic H1N1 influenza virus with circulating human and avian influenza viruses. 21
MALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19 21
Torque teno virus microRNA detection in cerebrospinal fluids of patients with neurological pathologies 21
SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein 20
Preliminary evidence on the use of Polyomavirus JC microRNA as biomarker of viral reactivation 19
Studio in vitro della capacità di riassortimento del nuovo virus umano dell’influenza A di origine suina H1N1. 17
In vitro and ex vivo detection of human polyomavirus JC microRNA 14
Lack of direct association between oral mucosal lesions and SARS-CoV- 2 in a cohort of patients hospitalised with COVID-19 14
Editorial: Torquetenovirus: predictive biomarker or innocent bystander in pathogenesis 13
Factors associated with death due to severe acute respiratory syndrome caused by influenza: Brazilian population study. 13
Totale 5.677
Categoria #
all - tutte 18.029
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.029


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019381 0 0 0 0 0 0 0 0 0 77 161 143
2019/20201.106 111 74 24 100 92 134 114 141 109 75 96 36
2020/2021829 61 47 55 126 38 110 34 82 59 101 55 61
2021/2022626 13 57 65 14 25 20 27 25 22 37 126 195
2022/20231.602 154 318 53 91 120 272 202 62 234 17 53 26
2023/2024536 26 87 116 38 39 34 31 110 14 41 0 0
Totale 5.721